About Dr. Lee
Dr. Jeffrey E. Lee is Professor and Chair of the Department of Surgical Oncology as well as Irving and Nadine Mansfield and Robert David Levitt Cancer Research Chair at the University of Texas MD Anderson Cancer Center in Houston, Texas. Dr. Lee received his AB from Dartmouth College and his MD from Stanford University School of Medicine. He completed a residency in surgery and a research fellowship in immunology at Stanford, followed by a clinical fellowship in surgical oncology at MD Anderson. He joined the faculty at MD Anderson in 1993. Dr. Lee’s clinical interests include the surgical management of patient with melanoma, pancreatic cancer and endocrine tumors.
Prior to assuming his role as Department Chair, Dr. Lee served for 17 years as Medical Director of the Ben Love/El Paso Corporation Melanoma and Skin Center. Dr. Lee is Co-Director of the Melanoma and Skin Cancer Research Program and recently completed a decade as Co-Director of MD Anderson’s NCI-sponsored Melanoma SPORE grant. A particular focus of his research is the role of genetics in melanoma progression. The overall goal of Dr. Lee’s research program has been to identify immune and inflammatory mechanisms controlling melanoma progression to help develop improved treatment strategies.
Dr. Lee’s laboratory’s prior investigations have identified specific polymorphisms in human leukocyte antigen (HLA) class II as well as blood levels of IL-12, CRP and interferon gamma as independent markers of disease progression and prognosis in melanoma patients. His Melanoma Genetics and Blood Biomarker Program continues to analyze results related to a genome-wide investigation of more than 800,000 single-nucleotide polymorphisms (SNPs) in over 1800 melanoma patients to identify loci most strongly linked with melanoma progression, with plans to use this information to inform comprehensive biologic risk models of melanoma progression that incorporate clinical, histopathologic, serologic, and genetic information.
Professor, Department of Surgical Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX
Department Chair, Department of Surgical Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX
Vice President, Department of Medical & Academic Affairs, Cancer Network, The University of Texas MD Anderson Cancer Center, Houston, TX
Co-Director, Division of Melanoma and Skin Cancer Research Program, The University of Texas MD Anderson Cancer Center, Houston
Executive Director, Department of Cancer Network, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX
|1984||Stanford University School of Medicine, Stanford, CA, USA, MD, Medicine|
|1979||Dartmouth College, Hanover, NH, USA, BA, Biochemistry|
|1991-1993||Fellowship, Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX|
|1990-1991||Chief Resident, General Surgery, Stanford University Medical Center, Stanford, CA|
|1987-1989||Research Fellow, Immunology, Stanford University School of Medicine, Stanford, CA|
|1984-1985||Internship, General Surgery, Stanford University Medical Center, Stanford, CA|
|1984-1990||Resident, General Surgery, Stanford University Medical Center, Stanford, CA|
External Advisory Board Member, NIH, New York University Melanoma SPORE, New York, NY, 2020 - Present
|2020||Society of Surgical Oncology, Fellow|
- Gu N, Dai W, Liu H, Ge J, Luo S, Cho E, Amos CI, Lee JE, Li X, Nan H, Yuan H, Wei Q. Genetic variants in TKT and DERA in the nicotinamide adenine dinucleotide phosphate pathway predict melanoma survival. Eur J Cancer 136:84-94, 2020. e-Pub 2020. PMID: 32659474.
- Altinmakas E, Perrier ND, Grubbs EG, Lee JE, Prieto VG, Ng CS. Diagnostic performance of adrenal CT in the differentiation of adenoma and pheochromocytoma. Acta Radiol 61(8):1080-1086, 2020. e-Pub 2019. PMID: 31791129.
- Day RW, Taylor BM, Bednarski BK, Tzeng CD, Gershenwald JE, Lee JE, Grubbs EG. Virtual Interviews for Surgical Training Program Applicants During COVID-19: Lessons Learned and Recommendations. Ann Surg 272(2):e144-e147, 2020. PMID: 32675519.
- Perri G, Prakash L, Qiao W, Varadhachary GR, Wolff R, Fogelman D, Overman M, Pant S, Javle M, Koay EJ, Herman J, Kim M, Ikoma N, Tzeng CW, Lee JE, Katz MHG. Postoperative chemotherapy benefits patients who received preoperative therapy and pancreatectomy for pancreatic adenocarcinoma. Ann Surg 271(6):996-1002, 2020. e-Pub 2019. PMID: 31895709.
- Maxwell JE, Gule-Monroe MK, Subbiah V, Hu M, Perrier ND, Cabanillas ME, Lee JE, Graham PH, Cote GJ, Busaidy NL, Grubbs EG. Novel use of a Clinical Laboratory Improvements Amendments (CLIA)-certified Cyclin-Dependent Kinase N2C (CDKN2C) loss assay in sporadic medullary thyroid carcinoma. Surgery 167:80-86, 2020. e-Pub 2019.
- Howe JR, Merchant NB, Conrad C, Keutgen XM, Hallet J, Drebin JA, Minter RM, Lairmore TC, Tseng JF, Zeh HJ, Libutti SK, Singh G, Lee JE, Hope TA, Kim MK, Menda Y, Halfdanarson TR, Chan JA, Pommier RF. NANETS Guidelines: The North American neuroendocrine Tumor Society Consensus Paper on the surgical management of pancreatic neuroendocrine tumors. Pancreas 49(1):1-33, 2020.
- Parker NH, Lee RE, O'Connor DP, Ngo-Huang A, Petzel MQB, Schadler K, Wang X, Xiao L, Fogelman D, Simpson R, Fleming JB, Lee JE, Tzeng CD, Sahai SK, Basen-Engquist K, Katz MHG. Supports and Barriers to Home-Based Physical Activity During Preoperative Treatment of Pancreatic Cancer: A Mixed-Methods Study. J Phys Act Health 16(12):1-10, 2019. e-Pub 2019. PMID: 31592772.
- Chen K, Liu H, Liu Z, Bloomer W, Amos CI, Lee JE, Li X, Nan H, Wei Q. Genetic variants in glutamine metabolic pathway genes predict cutaneous melanoma-specific survival. Mol Carcinog 58(11):2091-2103, 2019. e-Pub 2019. PMID: 31435991.
- Cloyd JM, Prakash L, Vauthey JN, Aloia TA, Chun YS, Tzeng CW, Kim MP, Lee JE, Katz MHG. The role of preoperative therapy prior to pancreatoduodenectomy for distal cholangiocarcinoma. Am J Surg 218(1):145-150, 2019. e-Pub 2018. PMID: 30224070.
- Fang S, Wang Y, Chun YS, Liu H, Ross MI, Gershenwald JE, Cormier JN, Royal RE, Lucci A, Schacherer CW, Reveille JD, Chen W, Sui D, Bassett RL, Wang LE, Wei Q, Amos CI, Lee JE. Association of common genetic polymorphisms with melanoma patient IL-12p40 blood levels, risk and outcomes. J Invest Dermatol 135(9):2266-72, 2015. e-Pub 2015. PMID: 25848976.
- Fang S, Wang Y, Sui D, Liu H, Ross MI, Gershenwald JE, Cormier JN, Royal RE, Lucci A, Schacherer CW, Gardner JM, Reveille JD, Bassett RL, Wang LE, Wei Q, Amos CI, Lee JE. C-reactive protein as a marker of melanoma progression. J Clin Oncol 33(12):1389-96, 2015. e-Pub 2015. PMID: 25779565.
- Fang S, Wang Y, Chun YS, Liu H, Ross MI, Gershenwald JE, Cormier JN, Royal RE, Lucci A, Schacherer CW, Reveille JD, Sui D, Bassett RL, Wang LE, Wei Q, Amos CI, Lee JE. The relationship between blood IL-12p40 level and melanoma progression. Int J Cancer 136(8):1874-80, 2015. e-Pub 2014. PMID: 25196740.
- Yin J, Liu H, Liu Z, Wang LE, Chen WV, Zhu D, Amos CI, Fang S, Lee JE, Wei Q. Genetic variants in Fanconi Anemia Pathway Genes BRca2 and FANCA Predict Melanoma Survival. J Invest Dermatol 135(2):542-50, 2015. e-Pub 2014. PMID: 25243787.
- Iles MM, Bishop DT, Taylor JC, Hayward NK, Brossard M, Cust AE, Dunning AM, Lee JE, Moses EK, Akslen LA, AMFS Investigators, Andresen PA, Avril MF, Azizi E, Scarrà GB, Brown KM, Debniak T, Elder DE, Friedman E, Ghiorzo P, Gillanders EM, Goldstein AM, Gruis NA, Hansson J, Harland M, Helsing P, Hocevar M, Höiom V, IBD investigators, Ingvar C, Kanetsky PA, Landi MT, Lang J, Lathrop GM, Lubinski J, Mackie RM, Martin NG, Molven A, Montgomery GW, Novakovic S, Olsson H, Puig S, Puig-Butille JA, QMEGA and QTWIN Investigators, Radford-Smith GL, Randerson-Moor J, SDH Study Group, van der Stoep N, van Doorn R, Whiteman DC, MacGregor S, Pooley KA, Ward SV, Mann GJ, Amos CI, Pharoah PD, Demenais F, Law MH, Newton Bishop JA, Barrett JH, GenoMEL Consortium. The effect on melanoma risk of genes previously associated with telomere length. J Natl Cancer Inst 106(10), 2014. e-Pub 2014. PMID: 25231748.
- Iles MM, Law MH, Stacey SN, Han J, Fang S, Pfeiffer R, Harland M, Macgregor S, Taylor JC, Aben KK, Akslen LA, Avril MF, Azizi E, Bakker B, Benediktsdottir KR, Bergman W, Scarrà GB, Brown KM, Calista D, Chaudru V, Fargnoli MC, Cust AE, Demenais F, de Waal AC, Debniak T, Elder DE, Friedman E, Galan P, Ghiorzo P, Gillanders EM, Goldstein AM, Gruis NA, Hansson J, Helsing P, Hocevar M, Höiom V, Hopper JL, Ingvar C, Janssen M, Jenkins MA, Kanetsky PA, Kiemeney LA, Lang J, Lathrop GM, Leachman S, Lee JE, Lubinski J, Mackie RM, Mann GJ, Martin NG, Mayordomo JI, Molven A, Mulder S, Nagore E, Novakovic S, Okamoto I, Olafsson JH, Olsson H, Pehamberger H, Peris K, Grasa MP, Planelles D, Puig S, Puig-Butille JA, Randerson-Moor J, Requena C, Rivoltini L, Rodolfo M, Santinami M, Sigurgeirsson B, Snowden H, Song F, Sulem P, Thorisdottir K, Tuominen R, Van Belle P, van der Stoep N, van Rossum MM, Wei Q, Wendt J, Zelenika D, Zhang M, Landi MT, Thorleifsson G, Bishop DT, Amos CI, Hayward NK, Stefansson K, Bishop JA, Barrett JH, GenoMEL Consortium, Q-MEGA and AMFS Investigators. A variant in FTO shows association with melanoma risk not due to BMI. Nat Genet 45(4):428-32, 2013. e-Pub 2013. PMID: 23455637.
- Perri G, Prakash L, Qiao W, Varadhachary GR, Wolff R, Fogelman D, Overman M, Pant S, Javle M, Koay EJ, Herman J, Kim M, Ikoma N, Tzeng CW, Lee JE, Katz MHG. Response and Survival Associated With First-line FOLFIRINOX vs Gemcitabine and nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma. JAMA Surg. e-Pub 2020. PMID: 32667641.
- Lucci A, Hall CS, Patel SP, Narendran B, Bauldry JB, Royal RE, Karhade M, Upshaw JR, Wargo J, Glitza IC, Wong MK, Amaria RN, Tawbi H, Diab A, Davies MA, Gershenwald JE, Lee JE, Hwu P, Ross MI. Circulating tumor cells and early relapse in node-positive melanoma. Clin Cancer Res. e-Pub 2020. PMID: 32015020.
- Thompson JF, Faries MB, Friedman EB, Lee JE, Balch CM. Surgical Management of Distant Melanoma Metastases. In: Cutaneous Melanoma. 6. Springer International Publishing: Switzerland, 1359-1402, 2020.